Sham Mailankody

8.5k total citations · 3 hit papers
147 papers, 3.3k citations indexed

About

Sham Mailankody is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Sham Mailankody has authored 147 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 62 papers in Oncology and 49 papers in Molecular Biology. Recurrent topics in Sham Mailankody's work include Multiple Myeloma Research and Treatments (85 papers), CAR-T cell therapy research (34 papers) and Protein Degradation and Inhibitors (24 papers). Sham Mailankody is often cited by papers focused on Multiple Myeloma Research and Treatments (85 papers), CAR-T cell therapy research (34 papers) and Protein Degradation and Inhibitors (24 papers). Sham Mailankody collaborates with scholars based in United States, Sweden and Iceland. Sham Mailankody's co-authors include Vinay Prasad, Ola Landgren, Neha Korde, Tito Fojo, Urvi A. Shah, Andrew W. Lo, Sigurður Y. Kristinsson, Victoria Kaestner, Ingemar Turesson and Sean M. Devlin and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Medicine.

In The Last Decade

Sham Mailankody

136 papers receiving 3.3k citations

Hit Papers

Research and Development Spending to Bring a Single Cance... 2017 2026 2020 2023 2017 2017 2023 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
    2017 294 citations Sham Mailankody et al. profile →
  2. The high price of anticancer drugs: origins, implications, barriers, solutions
    2017 281 citations Sham Mailankody et al. profile →
  3. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    2023 168 citations Sham Mailankody, Arun Balakumaran et al. profile →

Peers

Sham Mailankody
Kirsten B. Goldberg United States
Ali McBride United States
Robert C. Kane United States
Thomas E. Stinchcombe United States
Neeltje Steeghs Netherlands
Dickran Kazandjian United States
Francesco Pignatti Netherlands
Purvish M. Parikh India
Kouros Owzar United States
Erica L. Mayer United States
Kirsten B. Goldberg United States
Sham Mailankody
Citations per year, relative to Sham Mailankody Sham Mailankody (= 1×) peers Kirsten B. Goldberg

Countries citing papers authored by Sham Mailankody

Since Specialization
Citations

This map shows the geographic impact of Sham Mailankody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sham Mailankody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sham Mailankody more than expected).

Fields of papers citing papers by Sham Mailankody

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sham Mailankody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sham Mailankody. The network helps show where Sham Mailankody may publish in the future.

Co-authorship network of co-authors of Sham Mailankody

This figure shows the co-authorship network connecting the top 25 collaborators of Sham Mailankody. A scholar is included among the top collaborators of Sham Mailankody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sham Mailankody. Sham Mailankody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamadeh, Issam S., et al.. (2024). Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma. Frontiers in Oncology. 14. 1455464–1455464. 3 indexed citations
2.
3.
4.
Mitchell, Aaron Philip, Hannah E. Fuchs, Prabal K. De, et al.. (2024). Quality of Treatment Selection for Medicare Beneficiaries With Cancer. Journal of Clinical Oncology. 43(5). 524–535. 3 indexed citations
5.
Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations
6.
Lipitz‐Snyderman, Allison, Susan Chimonas, Sham Mailankody, et al.. (2023). Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations. Cancer Medicine. 12(7). 8063–8072. 1 indexed citations
7.
Gewirtz, Alexandra N., Sham Mailankody, Saad Z. Usmani, & Bianca Santomasso. (2023). IMMU-45. REVERSIBLE PARKINSONISM AFTER BCMA-DIRECTED CAR T CELL ADMINISTRATION. Neuro-Oncology. 25(Supplement_5). v152–v152. 1 indexed citations
8.
Firestone, Ross, Andriy Derkach, Kylee Maclachlan, et al.. (2023). P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S307–S308. 1 indexed citations
9.
Hultcrantz, Malin, Even H. Rustad, Venkata Yellapantula, et al.. (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. 28(10). 2160–2166. 1 indexed citations
10.
11.
Yellapantula, Venkata D., Malin Hultcrantz, Even H. Rustad, et al.. (2020). Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal. 10(1). 1 indexed citations
12.
Smith, Eric L., Sham Mailankody, Mette Stæhr, et al.. (2019). BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research. 7(7). 1047–1053. 67 indexed citations
13.
Beedie, Shaunna, Cindy H. Chau, David Venzon, et al.. (2019). Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. Scientific Reports. 9(1). 14884–14884. 5 indexed citations
14.
Yellapantula, Venkata D., Malin Hultcrantz, Even H. Rustad, et al.. (2019). Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal. 9(12). 101–101. 35 indexed citations
15.
Kazandjian, Dickran, Elizabeth Hill, Malin Hultcrantz, et al.. (2019). Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Genetics Research. 4 indexed citations
16.
Pianko, Matthew J., Jessica Flynn, Sean M. Devlin, et al.. (2018). Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood. 132(Supplement 1). 5591–5591.
17.
Þórðardóttir, Maríanna, Ebba K. Lindqvist, Sigrún H. Lund, et al.. (2018). Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE. 13(11). e0206047–e0206047. 21 indexed citations
18.
Wu, Shijie, Ruth M. Pfeiffer, Inhye E. Ahn, et al.. (2016). Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients. Clinical Cancer Research. 22(16). 4039–4044. 12 indexed citations
19.
Engels, Eric A., Ola Landgren, Régis Costello, et al.. (2014). Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation. 50(1). 146–147. 1 indexed citations
20.
Mailankody, Sham, Esther Mena, Constance M. Yuan, et al.. (2010). Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leukemia & lymphoma. 51(12). 2159–2170. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirsten B. Goldberg Breakdown of academic impact, for papers by Ali McBride Breakdown of academic impact, for papers by Robert C. Kane Breakdown of academic impact, for papers by Thomas E. Stinchcombe Breakdown of academic impact, for papers by Neeltje Steeghs Breakdown of academic impact, for papers by Dickran Kazandjian Breakdown of academic impact, for papers by Francesco Pignatti Breakdown of academic impact, for papers by Purvish M. Parikh Breakdown of academic impact, for papers by Kouros Owzar Breakdown of academic impact, for papers by Erica L. Mayer
Rankless by CCL
2026